השוואת שיטות

	מדדי דיכאון, חרדה ולחץ-21 (DASS-21)	סולם המילטון להערכת חרדה (HAM-A)	סולם החרדה והדיכאון של בית החולים (HADS)
תחום	פסיכולוגיה קלינית	פסיכולוגיה קלינית	פסיכולוגיה קלינית
משפחה	Process / pipeline	Process / pipeline	Process / pipeline
שנת המקור	1995	1959	1983
הוגה השיטה	Stephen H. Lovibond and Peter F. Lovibond	Max Hamilton	Andrew S. Zigmond and Richard P. Snaith
סוג	Three-dimensional mental health screening	Clinician-administered anxiety assessment	Anxiety and depression screening in medical populations
מקור מכונן	Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales. Psychology Foundation of Australia.	Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32(1), 50-55.	Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67(6), 361-370.
כינויים	DASS-21, DASS, DASS-42	HAM-A, HARS	HADS, HADS-A, HADS-D
קשורות	5	5	4
תקציר	The Depression Anxiety Stress Scales-21 (DASS-21) is a 21-item self-report instrument measuring three correlated but distinct dimensions of psychological distress: depression, anxiety, and stress. Developed by Lovibond and Lovibond in 1995, the DASS-21 is a short form of the original 42-item DASS. It has become widely used in research and clinical settings for its brevity, multidimensional structure, and strong psychometric properties.	The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool for quantifying the severity of anxiety symptoms in adults. Developed by Max Hamilton in 1959, it remains one of the most widely used instruments for evaluating anxiety in clinical and research settings. The scale measures both psychological and somatic manifestations of anxiety across 14 items.	The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report instrument measuring anxiety and depression symptoms in medically ill populations. Developed by Zigmond and Snaith in 1983, the HADS was specifically designed for hospital and general medical settings where somatic symptoms of medical illness may confound assessment. It remains the standard anxiety-depression measure in medical, oncology, and cardiac populations worldwide.